Wallaby Medical Files IPO Prospectus Following Landmark €500M Acquisition of German Neurovascular Leader phenox

In April 2022, Wallaby Medical Holdings Limited (hereinafter referred to as “Wallaby Medical”) announced the completion of its acquisition of phenox GmbH and its subsidiary femtos GmbH (collectively, “phenox”). The total consideration for this acquisition was approximately €500 million (including milestone payments).It is one of the largest cross-border M&A transactions in the global medical device industry in recent years.

Data shows that Wallaby Medical, founded in 2015, is an international company dedicated to the research, development, and production of innovative products for the treatment of cerebrovascular diseases. Headquartered in Shanghai, China, with its R&D center located in the United States, the company has possessed an international ethos and culture since its inception. Leveraging internationally leading products, Wallaby Medical has successfully expanded its sales to more than 30 countries and regions, including the United States, China, the European Union, the United Kingdom, and Chile, achieving significant sales scale in major developed markets such as the United States and Europe.

Founded in 2005 and headquartered in Bochum, Germany, phenox is a global innovation leader in the field of neurointervention, dedicated to providing technologies and solutions for the treatment of neurovascular diseases. Its extensive product portfolio covers devices for ischemic stroke, hemorrhagic stroke, and vascular access. Leveraging its innovative and clinical advantages, phenox products are sold in more than 45 countries worldwide.

This acquisition will further enhance the global recognition of China’s domestically produced neurointerventional medical devices. Meanwhile, it also demonstrates that high-quality neurointerventional medical devices independently developed in China have met international standards.

Following the acquisition, Wallaby Medical has secured a more robust portfolio of neurointerventional products, an international R&D team dedicated to innovation, and broader market coverage, establishing itself as a leading enterprise in the global neurointerventional field.

In the business world, acquisitions are never easy, as evidenced by the recent high-profile Twitter acquisition case.

Nevertheless, Wallaby Medical’s acquisition of phenox proceeded smoothly, with both parties viewing it as a win-win outcome. Through this acquisition, Wallaby Medical has become a leading enterprise in the global neurointerventional field, while phenox will leverage Wallaby Medical’s robust resources to further develop new technologies and expand its product presence into additional markets.

Liu Bing, founder and chairman of Wallaby Medical, revealed: “During the acquisition negotiation phase, approximately 20 companies participated in the bidding competition. Among them,”Some companies offered higher quotes, but phenox ultimately chose Wallaby Medical."This is because Wallaby Medical had previously established a strong relationship of trust with phenox, and the two companies are highly complementary in terms of product portfolios and market channels, creating significant synergies post-merger."

In terms of trust, Wallaby Medical entered into a strategic partnership with phenox in 2019, granting phenox exclusive rights to sell Wallaby Medical’s Avenir in the U.S. and European markets.^TMMechanically detachable coils; exclusively distributes Wallaby Medical’s Esperance® aspiration catheter in the U.S. market. Professor Hermann Monstadt, founder of phenox, stated, “Through our collaboration with Wallaby Medical, I have come to deeply admire this company, and we both share a strong mutual commitment to quality and innovation.”

In terms of product portfolios, Wallaby Medical offers mechanically detachable coils, aspiration catheters, and distal access catheters, while phenox provides flow diverters, stent retrievers, scaffold coil stents, and bifurcation aneurysm embolization implants. The two companies’ product lines are complementary, enabling the formation of a more comprehensive portfolio in subfields such as ischemic stroke, hemorrhagic stroke, and vascular access, thereby delivering comprehensive neurointerventional technologies and solutions to stroke patients worldwide.

In terms of market channels, Wallaby Medical’s products are sold in over 30 countries and regions worldwide, while phenox’s products are available in more than 45 countries. Each company has its own strongholds: Wallaby Medical boasts robust distribution networks in China and Japan, whereas phenox holds significant channel advantages in the United States and Germany. By integrating and optimizing their respective market channels, and leveraging a comprehensive product portfolio, the two parties can achieve greater synergies, expand their global reach, and help more stroke patients worldwide.

Based on the above considerations, Phenox ultimately chose Wallaby Medical. Meanwhile, the mutual trust and recognition between Wallaby Medical and Phenox facilitated smoother resource integration.

According to reports, following the completion of the merger, An Muke, founder of Wallaby Medical, will serve as Chief Executive Officer, while Professor Hermann Monstadt, founder of phenox, will assume the role of Managing Director of phenox. All existing product brands under phenox will be retained. Meanwhile, Wallaby Medical has made comprehensive arrangements for phenox’s talent team to ensure their continued development alongside the company.

Overall, based on mutual trust, complementarity, and reciprocal recognition, Wallaby Medical and phenox successfully completed acquisition negotiations and smoothly proceeded with resource integration.

From the acquirer’s perspective, with €500 million in hand and facing the complex and fragmented medical device subsectors, Wallaby Medical chose to acquire phenox, a leading German company in neurointervention.

This is because Wallaby Medical recognizes the complementarity it shares with phenox in terms of product portfolio, geographic presence, and market channels, as previously mentioned. Furthermore, unlike other neurointerventional companies that have expanded into peripheral or coronary product lines, Wallaby Medical remains dedicated to the research, development, and manufacturing of innovative neurointerventional devices, maintaining a strong positive outlook on the neurointerventional market.

Wallaby Medical believes that, as one of the major global markets for neurointervention, China’s market size will grow rapidly.

First, stroke is a severe disease with high mortality and disability rates, primarily affecting individuals aged 65 and older. According to data from the Seventh National Population Census, the proportion of China’s population aged 65 and above accounts for 13.5% of the total population, indicating a progressively deepening aging trend. The number of stroke patients in China is expected to continue rising, leading to steady expansion of the neurointerventional market.

Secondly, national policy support is driving the development of the neurointerventional industry. For instance, the “Healthy China 2030” Planning Outline has elevated stroke prevention and control to a national strategy, neurointerventional devices are being gradually included in medical insurance coverage, and the country is vigorously promoting the construction of stroke centers. Currently, the number of stroke centers is growing at an annual rate of 37%, and this rapid growth is expected to continue over the next decade.

Finally, as neurointerventional companies intensify market education and physician training, a growing number of doctors are beginning to recognize, learn, and adopt neurointerventional procedures. With the rising volume of such procedures, the neurointerventional market size is poised for rapid growth. Research institutions project that China’s neurointerventional market will exceed RMB 30 billion by 2025.

In fact, beyond China, the global neurointerventional market also holds significant growth potential. For instance, data released by Guosen Securities shows that in the United States, one of the most mature markets worldwide, the penetration rate for stroke treatment is only approximately 11.8%, indicating substantial room for improvement. Therefore, Wallaby Medical remains optimistic about and continues to strategically position itself in the neurointerventional market.

Nevertheless, it is worth noting that there are numerous neurointerventional companies worldwide, with over 20 such enterprises in the Chinese market alone. Meanwhile, prominent multinational medical device manufacturers, such as Medtronic and Stryker, have also established a presence in the neurointerventional market.

In response, Liu Bing, Chairman of Wallaby Medical, stated, “Following the acquisition of phenox, Wallaby Medical has become a company in the neurointerventional field that can stand shoulder to shoulder with renowned multinational medical device companies. Compared with domestic and international enterprises, Wallaby possesses unique differentiated advantages.”

Compared with overseas companies, Wallaby Medical enjoys localization advantages in the Chinese market and benefits from the brand and channel strengths of phenox in international markets. Meanwhile, Wallaby Medical maintains closer collaborations with domestic physicians, granting it significant advantages in product research and development iteration.

Compared with domestic enterprises, Wallaby Medical boasts a rich product portfolio, enabling it to provide patients with comprehensive neurointerventional solutions. The company’s team comprises top-tier talent from the United States, Europe, China, and other regions, possessing an international perspective and world-class innovation and R&D capabilities. Furthermore, Wallaby Medical has integrated market channels across China, Japan, the United States, and Europe, demonstrating robust global market development capabilities.

Based on the aforementioned advantages, Wallaby Medical is poised to accelerate its growth and become the global leader in treating stroke patients.

Wallaby Medical has completed its acquisition of phenox and is currently integrating resources. Meanwhile, the global neurointerventional industry is undergoing significant transformation.

In the Chinese market, centralized procurement has been launched for neurointerventional products such as coils and microcatheters, and it is expected that normalized centralized procurement will cover other neurointerventional products. Meanwhile, more than 20 domestic neurointerventional companies are vying for market share, resulting in intense competition.

In overseas markets, the neurointerventional industry is equally competitive, with a number of Chinese companies beginning to export their devices and make inroads into the international market.

In response to the increasingly intense market competition, Wallaby Medical will increase its investment in technology and solutions to research, develop, and manufacture more innovative neurointerventional devices, while continuing to pursue a global layout.

Specifically, Wallaby Medical will develop innovative products through its world-class R&D capabilities and meet patient needs with safer and more effective clinical solutions, thereby gaining a competitive edge in the market.

Wallaby Medical will also strengthen its promotional efforts in global markets, including Europe, the United States, China, and Japan. It is understood that since its inception, Wallaby Medical has adhered to an internationalization strategy, pursuing a distinctive approach to expanding into overseas markets and establishing a significant sales presence in key international regions. To date, Wallaby Medical’s products have gained recognition in the global market.

Based on Wallaby Medical’s advantages in products, brand, and reputation, we expect it to accelerate its development in the Chinese and global markets.